BioStem Technologies, Inc. (BSEM)
USD 16.5
(-2.94%)
USD 16.5
(-2.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.77 Million USD | -66.16% |
| 2022 | -4.68 Million USD | -191.56% |
| 2021 | -1.6 Million USD | 12.84% |
| 2020 | -1.84 Million USD | 67.85% |
| 2019 | -5.72 Million USD | 26.24% |
| 2018 | -7.76 Million USD | -60.82% |
| 2017 | -4.83 Million USD | -42.73% |
| 2016 | -3.38 Million USD | -43.3% |
| 2015 | -2.36 Million USD | -1048.58% |
| 2014 | -205.59 Thousand USD | 8.66% |
| 2013 | -225.08 Thousand USD | 4.95% |
| 2012 | -236.81 Thousand USD | 55.08% |
| 2011 | -527.13 Thousand USD | -36.68% |
| 2010 | -385.67 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 4.6 Million USD | 263.03% |
| 2024 Q2 | 8.81 Million USD | 91.38% |
| 2023 FY | -7.77 Million USD | -66.16% |
| 2023 Q2 | -2.47 Million USD | -56.0% |
| 2023 Q4 | -2.82 Million USD | -633.37% |
| 2023 Q3 | 529.93 Thousand USD | 121.41% |
| 2023 Q1 | -1.58 Million USD | 56.48% |
| 2022 Q3 | -774.98 Thousand USD | -331.37% |
| 2022 FY | -4.68 Million USD | -191.56% |
| 2022 Q4 | -3.64 Million USD | -370.31% |
| 2022 Q1 | -680.1 Thousand USD | -74.06% |
| 2022 Q2 | 334.95 Thousand USD | 149.25% |
| 2021 FY | -1.6 Million USD | 12.84% |
| 2021 Q4 | -390.72 Thousand USD | 33.31% |
| 2021 Q1 | -343.07 Thousand USD | 21.15% |
| 2021 Q2 | -191.85 Thousand USD | 44.08% |
| 2021 Q3 | -585.85 Thousand USD | -205.37% |
| 2020 Q1 | -247.39 Thousand USD | -1.73% |
| 2020 Q3 | -589.83 Thousand USD | -3.49% |
| 2020 Q4 | -435.06 Thousand USD | 26.24% |
| 2020 FY | -1.84 Million USD | 67.85% |
| 2020 Q2 | -569.96 Thousand USD | -130.39% |
| 2019 Q1 | -2.27 Million USD | 0.0% |
| 2019 FY | -5.72 Million USD | 26.24% |
| 2019 Q4 | -243.19 Thousand USD | 80.48% |
| 2019 Q3 | -1.24 Million USD | 36.67% |
| 2019 Q2 | -1.96 Million USD | 13.49% |
| 2018 Q1 | -1.26 Million USD | -854.06% |
| 2018 FY | -7.76 Million USD | -60.82% |
| 2018 Q2 | -888.51 Thousand USD | 29.86% |
| 2017 Q3 | -1.58 Million USD | 4.27% |
| 2017 Q4 | -132.78 Thousand USD | 91.63% |
| 2017 FY | -4.83 Million USD | -42.73% |
| 2017 Q1 | -1.2 Million USD | -171.71% |
| 2017 Q2 | -1.65 Million USD | -37.97% |
| 2016 Q1 | -488.76 Thousand USD | 50.13% |
| 2016 Q2 | -2.17 Million USD | -345.35% |
| 2016 Q3 | -2.44 Million USD | -12.11% |
| 2016 Q4 | 1.67 Million USD | 168.64% |
| 2016 FY | -3.38 Million USD | -43.3% |
| 2015 Q3 | -376.04 Thousand USD | 49.2% |
| 2015 Q4 | -980.06 Thousand USD | -160.63% |
| 2015 Q2 | -740.2 Thousand USD | -179.23% |
| 2015 Q1 | -265.09 Thousand USD | -1262.72% |
| 2015 FY | -2.36 Million USD | -1048.58% |
| 2014 Q4 | -19.45 Thousand USD | 73.25% |
| 2014 Q2 | -112.95 Thousand USD | -41.49% |
| 2014 FY | -205.59 Thousand USD | 8.66% |
| 2014 Q1 | -79.83 Thousand USD | 47.24% |
| 2014 Q3 | -72.72 Thousand USD | 35.62% |
| 2013 Q3 | 4418.00 USD | 0.0% |
| 2013 Q1 | -78.18 Thousand USD | 0.0% |
| 2013 FY | -225.08 Thousand USD | 4.95% |
| 2013 Q4 | -151.31 Thousand USD | -3525.01% |
| 2013 Q2 | - USD | 100.0% |
| 2012 FY | -236.81 Thousand USD | 55.08% |
| 2011 FY | -527.13 Thousand USD | -36.68% |
| 2010 FY | -385.67 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -5420.641% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1032.392% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4435.59% |
| CytoDyn Inc. | -18.05 Million USD | 56.922% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 86.813% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -1076112.144% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -328.282% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -54.207% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -25871.451% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4186.288% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 19.851% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 85.986% |
| SQZ Biotechnologies Company | -75.82 Million USD | 89.741% |
| Resverlogix Corp. | -12.74 Million USD | 38.984% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1896.809% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 179.846% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -216.821% |
| Mesoblast Limited | -84.14 Million USD | 90.756% |
| GB Sciences, Inc. | -1.42 Million USD | -447.618% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1032.392% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 56.413% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -128.459% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -17.012% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -145.527% |
| ContraFect Corporation | -56.88 Million USD | 86.326% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -182.785% |
| LadRx Corporation | -3.82 Million USD | -103.445% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 50.982% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -595.171% |
| CSL Limited | 3.7 Billion USD | 100.21% |
| Biomind Labs Inc. | -1 Million USD | -670.498% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -735.209% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 109.504% |
| Nascent Biotech, Inc. | -2.22 Million USD | -248.852% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 89.164% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 258.276% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 319.745% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -406.427% |
| Marizyme, Inc. | -34.08 Million USD | 77.179% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 6.839% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1277.484% |
| Zenith Capital Corp. | -8.94 Million USD | 13.016% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -172.898% |
| Halberd Corporation | -75.05 Thousand USD | -10265.049% |
| Genus plc | 6.4 Million USD | 221.546% |
| Pharming Group N.V. | -4.87 Million USD | -59.42% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -291.596% |
| IMV Inc. | -38.67 Million USD | 79.884% |
| Affymax, Inc. | -15.04 Million USD | 48.299% |
| SYBLEU INC | -149.18 Thousand USD | -5114.485% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -645.112% |
| Enzolytics Inc. | -2.14 Million USD | -262.015% |
| argenx SE | -425.04 Million USD | 98.17% |
| AVAX Technologies, Inc. | 6.69 Million USD | 216.228% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -454.852% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -482.506% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -107.637% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -30805.717% |
| Cell Source, Inc. | -4.32 Million USD | -79.846% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1510.346% |
| Q BioMed Inc. | -3.44 Million USD | -125.764% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -83.535% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -519.345% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -196.057% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -70.789% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 85.849% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -168.125% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1071.531% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -690.503% |
| Skye Bioscience, Inc. | -13.67 Million USD | 43.102% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -317.244% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -288.026% |
| ONE Bio Corp. | 13.68 Million USD | 156.857% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -302.511% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -591.522% |
| Agentix Corp. | -1.37 Million USD | -467.081% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -166.454% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -392.541% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44552.827% |
| Kadimastem Ltd | -3.04 Million USD | -155.866% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2872.18% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1772.289% |
| NovAccess Global Inc. | -2.46 Million USD | -215.352% |
| Itoco Inc. | -919.14 Thousand USD | -746.331% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3434.642% |
| Qrons Inc. | -643.67 Thousand USD | -1108.521% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1302.753% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.129% |
| International Stem Cell Corporation | -663 Thousand USD | -1073.298% |
| Bioxytran, Inc. | -3.82 Million USD | -103.63% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -14677.677% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -38144.685% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 78.55% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -380.777% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -957.162% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -150.047% |
| Neutra Corp. | -229.48 Thousand USD | -3289.736% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 55.648% |
| PureTech Health plc | -146.19 Million USD | 94.679% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 63.804% |
| IXICO plc | -1.43 Million USD | -441.334% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 18.038% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 93.614% |
| CSL Limited | 3.81 Billion USD | 100.204% |
| Cellectis S.A. | -108.85 Million USD | 92.854% |